Stockscreener 앱 받기
0.3683
3.56%
-0.0136
시장 영업 전:
.36
-0.0083
-2.25%
전일 마감가:
$0.3819
열려 있는:
$0.3816
하루 거래량:
193.67K
Relative Volume:
0.37
시가총액:
$14.96M
수익:
$656.60K
순이익/손실:
$-16.79M
주가수익비율:
-0.3428
EPS:
-1.0743
순현금흐름:
$-11.12M
1주 성능:
-5.03%
1개월 성능:
-8.38%
6개월 성능:
-31.22%
1년 성능:
-60.03%
1일 변동 폭
$0.366
$0.3843
1주일 범위
$0.366
$0.4269
52주 변동 폭
$0.2382
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
명칭
Scienture Holdings Inc
전화
(800) 261 0281
주소
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, POM, WGRX
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.3683 | 14.96M | 656.60K | -16.79M | -11.12M | -1.0743 |
HITI
High Tide Inc
|
2.21 | 195.07M | 452.61M | -35.30M | 13.25M | -0.3863 |
PETS
Petmed Express Inc
|
1.79 | 38.24M | 182.67M | -64.87M | -22.92M | -3.1193 |
POM
Pomdoctor Ltd Adr
|
1.33 | 9.92M | 0 | 0 | 0 | 0.00 |
WGRX
Wellgistics Health Inc
|
2.82 | 7.09M | 14.03M | -76.59M | -13.73M | -41.45 |
Scienture Holdings Inc 주식(SCNX)의 최신 뉴스
Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Scienture stock rises after adding 12.5M covered lives for Arbli - Investing.com Nigeria
Scienture stock rises after adding 12.5M covered lives for Arbli By Investing.com - Investing.com Australia
Scienture (SCNX) Advances Commercialization of Arbli - GuruFocus
Scienture expands payor coverage for Arbli by 12.5M lives - Investing.com
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide - marketscreener.com
Scienture Holdings Inc (SCNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scienture Holdings Inc (SCNX) Institutional Confidence - TradingKey
Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scienture Holdings Inc (SCNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Scienture Holdings Inc (SCNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Scienture Holdings Inc (SCNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX) - The Globe and Mail
Maxim Group Maintains Scienture Holdings(SCNX.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
SCNX Q1 2026 Earnings: Loss Narrower Than Expected as Stock Declines 4.66%Dividend Earnings Report - newsline.com
Exclusive: Scienture expands coverage for opioid overdose treatment ahead of commercial launch - MSN
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentEarnings Weakness Phase - newsline.com
Scienture Holdings (SCNX) Investor Relations, Earnings Summary & Outlook - Quartr
Scienture Holdings Inc. (SCNX) Rallies 6.43% to $0.38, Nears Key ResistanceRSI Oversold Picks - newsline.com
Scienture Holdings Inc at Small Cap Showcase & WTR Insights Conference Transcript - GuruFocus
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive MomentumCore Business Growth - newsline.com
Scienture’s naloxone nasal spray added to national health plan By Investing.com - Investing.com South Africa
Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team - marketscreener.com
Scienture’s naloxone nasal spray added to national health plan - Investing.com UK
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team - The Manila Times
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch - Benzinga
Scienture Holdings (SCNX) Slides 5.26% as Stock Tests Key Support LevelsIchimoku TK Cross - newsline.com
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC - Corsicana Daily Sun
Scienture (SCNX) Secures Patent for Rezenopy Nasal Spray - GuruFocus
Scienture Secures US Patent Protection for Rezenopy Through 2041 - marketscreener.com
Scienture receives patent for naloxone nasal spray until 2041 By Investing.com - Investing.com South Africa
Scienture receives patent for naloxone nasal spray until 2041 - Investing.com
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041 - The Manila Times
New high-dose naloxone nasal spray wins U.S. patent to 2041 - Stock Titan
Scienture Holdings, Inc. (SCNX) 8-K Filing: Director Changes and Company Details for May 2026 - Minichart
Scienture Holdings Announces CFO Resignation, Names Interim Successor - The Globe and Mail
ScientureEric Sherb resigns as CFO effective May 26, 2026 - marketscreener.com
Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026 - marketscreener.com
SCNX Q1 2026 Earnings Narrowerthanexpected loss drives positive surprise despite revenue absence - The Legal Advocate
SCNX Q1 2026 Earnings: Significant EPS Beat Despite Revenue AbsenceEarnings Preview - The Legal Advocate
SCNX Q1 2026 Earnings: Narrower-than-expected loss drives positive surprise despite revenue absencePre-Earnings Drift - newsline.com
Scienture Holdings (SCNX) Holds Near Support as Slight Decline PersistsATR Trailing Stop - Město Břeclav
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: EPS Surprise of 64% Narrows Loss Amid Strategic Progress - The Legal Advocate
SCNX Q1 2026 Earnings: Significant EPS Beat Despite Lack of RevenueNet Income Trends - Newser
Scienture Holdings Reports 449% Revenue Growth and 95.6% Gross Margin Expansion in Q1 2026, Driven by Arbli and REZENOPY Launches - Minichart
Scienture Holdings Inc (SCNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.32%
자본화:
|
볼륨(24시간):